Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 6:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 3 Interventional Accepts healthy volunteers

Maintenance Treatment for Abstinent Smokers

NCT00063323
Conditions
Tobacco Use Disorder
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 75 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
New York, New York
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation

NCT00419731
Conditions
Tobacco Use Disorder
Interventions
Bupropion, Bupropion + Naltrexone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Smoking Cessation
Interventions
Bupropion SR, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
53
States / cities
Fairhope, Alabama • Peoria, Arizona • Phoenix, Arizona + 46 more
Conditions
Obesity
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, fMRI scan
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Upton, New York
Conditions
Obesity
Interventions
Zonisamide SR placebo/ bupropion SR placebo, Zonisamide SR placebo/ bupropion SR 360 mg/day, Zonisamide SR 120 mg/day/ bupropion SR placebo, Zonisamide SR 360 mg/day/ bupropion SR placebo, Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day, Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Fairhope, Alabama • La Jolla, California • Denver, Colorado + 17 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tailored Tobacco Quitline for Rural Veterans

NCT01592695
Conditions
Cigarette Smoking
Interventions
Nicotine replacement therapy - transdermal nicotine patch, Tailored behavioral intervention, Tobacco quit line referral, Nicotine replacement therapy - nicotine gum, Nicotine replacement therapy - nicotine lozenge, Bupropion Sustained Release, Varenicline, Combination pharmacotherapy - transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - transdermal nicotine patch + bupropion, Alcohol use risk reduction, Behavioral activation for the treatment of depression, Behavioral management of post-cessation weight gain
Drug · Behavioral
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders
Interventions
bupropion SR, Cognitive Behavioral Group Therapy, nicotine replacement therapy
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Obesity, Overweight
Interventions
NB, CLI, Usual Care
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Denver, Colorado • St Louis, Missouri • Cary, North Carolina + 12 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns

NCT02078180
Conditions
Depression
Interventions
generic bupropion
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, Bupropion, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Completed Not applicable Interventional Results available

Bupropion in the Treatment of Methamphetamine Dependence

NCT00572234
Conditions
Methamphetamine Use Disorder
Interventions
bupropion SR
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Omaha, Nebraska
Conditions
Depression
Interventions
naltrexone SR 32 mg/ bupropion SR 360 mg daily
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Mason, Ohio
Conditions
Smoking, Myocardial Infarction, Unstable Angina, Cardiovascular Disease
Interventions
bupropion SR (sustained-release)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Major Depression, End Stage Renal Disease
Interventions
Fluoxetine, Bupropion
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed Phase 2 Interventional Accepts healthy volunteers

Bupropion for Smoking Cessation in Pregnancy

NCT01875172
Conditions
Smoking Cessation, Pregnancy
Interventions
Bupropion SR, placebo, smoking cessation counseling
Drug · Behavioral
Lead sponsor
Watching Over Mothers & Babies Foundation
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Bipolar Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Binge-eating Disorder, Obesity
Interventions
NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Roux en Y Gastric Bypass
Interventions
Bupropion SR and XL
Drug
Lead sponsor
North Dakota State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Nicotine Dependence, Overweight, Obesity
Interventions
NB32, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California
Conditions
Cigarette Smoking, Tobacco Smoking, Tobacco Use Disorder
Interventions
Sustained Care, Standard Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Salem, Massachusetts • Pittsburgh, Pennsylvania
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Placebo, Intensive group lifestyle modification counseling
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Gainesville, Florida + 5 more
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Nicotine Patch Pretreatment for Smoking Cessation in PTSD

NCT00625131
Conditions
Stress Disorders, Posttraumatic, Tobacco Use Disorder
Interventions
Nicotine, Cognitive Behavioral Therapy for Smoking Cessation, Bupropion Sustained Release (SR), Placebo patch
Drug · Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina